Bupivacaine

Generic Name: Bupivacaine

Brand Names: Exparel, Kenalog, Marbeta, Marcaine, Marcaine With Epinephrine, Marvona Suik, P-Care M, P-Care MG, P-care, Posimir, Readysharp Anesthetics Plus Ketorolac, Readysharp-A, Readysharp-p40, Readysharp-p80, Sensorcaine, Sensorcaine With Epinephrine, Vivacaine, Xaracoll, Exparel liposomal

Drug Type: Small Molecule

Chemical Formula: C_₁₈H_₂₈N_₂O

CAS Number: 38396-39-3

Unique Ingredient Identifier: Y8335394RO

Background: Bupivacaine is a widely used local anesthetic agent.

Indication: As an implant, bupivacaine is indicated in adults for placement into the surgical site to produce postsurgical analgesia for up to 24 hours following open inguinal hernia repair.

Bupivacaine, in liposome suspension, is indicated in patients aged 6 years and older for single-dose infiltration to produce postsurgical local analgesia. In adults, it is also indicated as an interscalene brachial plexus nerve block to produce postsurgical regional analgesia.

Bupivacaine, in combination with meloxicam, is indicated for postsurgical analgesia in adult patients for up to 72 hours following foot and ankle, small-to-medium open abdominal, and lower extremity total joint arthroplasty surgical procedures.

Bupivacaine, alone or in combination with epinephrine, is indicated in adults for the production of local or regional anesthesia or analgesia for surgery, dental and oral surgery procedures, diagnostic and therapeutic procedures, and for obstetrical procedures. Specific concentrations and presentations are recommended for each type of block indicated to produce local or regional anesthesia or analgesia. Finally, its use is not indicated in all blocks given clinically significant risks associated with use.

Associated Conditions: Acute Gouty Arthritis, Adrenocortical Insufficiency, Alopecia Areata (AA), Ankylosing Spondylitis (AS), Berylliosis, Bullous dermatitis herpetiformis, Congenital Adrenal Hyperplasia (CAH), Congenital Hypoplastic Anemia, Dermatomyositis (DM), Discoid Lupus Erythematosus (DLE), Edema of the cerebrum, Epicondylitis, Hemolytic Anemia, Hypercalcemia caused by Cancer, Keloids Scars, Leukemias, Mycosis Fungoides (MF), Necrobiosis lipoidica diabeticorum, Ocular Inflammation, Ophthalmia, Sympathetic, Osteoarthritis (OA), Pain, Labor, Polymyositis, Postoperative pain, Psoriatic Arthritis, Psoriatic plaque, Pure Red Cell Aplasia, Regional Enteritis, Rheumatoid Arthritis, Secondary thrombocytopenia, Stevens-Johnson Syndrome, Synovitis, Systemic Lupus Erythematosus, Temporal Arteritis, Trichinosis, Tuberculous Meningitis, Ulcerative Colitis, Uveitis, Acute Bursitis, Acute Idiopathic Nephrotic Syndrome, Acute Lupus Erythematosus, Acute Multiple sclerosis, Acute Rheumatic heart disease, unspecified, Acute nonspecific tenosynovitis, Cystic tumors of aponeurosis, Cystic tumors of tendon, Disseminated Pulmonary Tuberculosis (TB), Exfoliative erythroderma, Inflammatory lesions of granuloma annulare, Inflammatory lesions of lichen planus, Inflammatory lesions of lichen simplex, Non-suppurative Thyroiditis, Permphigus, Severe Allergic Reactions

Associated Therapies: General Anesthesia, Local Anaesthesia therapy, Regional nerve block therapy

Clinical Trials

Laparoscopic Assisted Plane Block (LAPB) Trial

Phase 4

Terminated

Conditions: Opioid Use

Interventions: Drug: Bupivacaine
Drug: Exparel 266 milligram Per 20 ML Injection
Drug: Saline

First Posted Date: 2018-11-05

Last Posted Date: 2021-07-01

Lead Sponsor: Santa Barbara Cottage Hospital

Target Recruit Count: 34

Registration Number: NCT03730402

Locations: 🇺🇸
Santa Barbara Cottage Hospital, Santa Barbara, California, United States

The Use Of Liposomal Bupivacaine For Pain Control

Phase 4

Completed

Conditions: Pain, Breast

Interventions: Drug: Liposomal Bupivacaine
Drug: Bupivacaine

First Posted Date: 2018-10-29

Last Posted Date: 2022-10-27

Lead Sponsor: Wake Forest University Health Sciences

Target Recruit Count: 3

Registration Number: NCT03722927

Locations: 🇺🇸
Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States

Comparison of Vasopressor Boluses for Management of Hypotension After Spinal Anesthesia

Phase 4

Conditions: Spinal Anesthetic Toxicity
Cesarean Section Complications

Interventions: Drug: Norepinephrine 10 mcg
Drug: Norepinephrine 6 mcg
Drug: Bupivacaine Hydrochloride
Drug: Norepinephrine infusion

First Posted Date: 2018-10-19

Last Posted Date: 2021-09-27

Lead Sponsor: Cairo University

Target Recruit Count: 86

Registration Number: NCT03712111

Locations: 🇪🇬
Ahmed Mohamed Hasanin, Cairo, Egypt

Bupivacaine HCl PK and Safety in Augmentation Mammoplasty

Phase 4

Completed

Conditions: Analgesia

Interventions: Drug: Bupivacaine HCl

First Posted Date: 2018-10-15

Last Posted Date: 2018-12-07

Lead Sponsor: Heron Therapeutics

Target Recruit Count: 30

Registration Number: NCT03705065

Locations: 🇺🇸
Hermann Drive Surgical Hospital, Houston, Texas, United States

Liposomal Bupivicaine for Skin Graft Donor Sites in Burn Patients

Early Phase 1

Terminated

Conditions: Postoperative Pain
Burns

Interventions: Drug: Exparel

First Posted Date: 2018-10-15

Last Posted Date: 2023-03-02

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 6

Registration Number: NCT03705637

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

ED50 and ED95 of Intrathecal Hyperbaric Bupivacaine With Fentanyl for Transurethral Prostatectomy in Elderly Patients

Not Applicable

Completed

Conditions: Old Age

Interventions: Drug: Bupivacaine

First Posted Date: 2018-10-12

Last Posted Date: 2022-03-21

Lead Sponsor: Hallym University Kangnam Sacred Heart Hospital

Target Recruit Count: 13

Registration Number: NCT03704441

Locations: 🇰🇷
Kangnam sacred heart hospital, Seoul, Yeongdeungpo-gu, Korea, Republic of

Comparing Liposomal Bupivacaine Versus Standard Bupivacaine in Colorectal Surgery

Phase 3

Completed

Conditions: Colorectal Surgery

Interventions: Drug: liposomal Bupivacaine
Drug: Bupivacaine Hydrochloride

First Posted Date: 2018-10-11

Last Posted Date: 2023-05-17

Lead Sponsor: Indiana University

Target Recruit Count: 90

Registration Number: NCT03702621

Locations: 🇺🇸
Indiana University Hospital, Indianapolis, Indiana, United States

Multicenter Study for Pediatric Subjects Evaluating Pharmacokinetics and Safety of EXPAREL

Phase 3

Completed

Conditions: Postoperative Pain Management

Interventions: Drug: Exparel
Drug: 0.5% Bupivacaine HCl

First Posted Date: 2018-09-24

Last Posted Date: 2021-01-06

Lead Sponsor: Pacira Pharmaceuticals, Inc

Target Recruit Count: 98

Registration Number: NCT03682302

Locations: 🇺🇸
Shriners Hospitals for Children-Chicago, Chicago, Illinois, United States
🇺🇸
Duke University Medical Center, Durham, North Carolina, United States
🇺🇸
Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States

and more 14 locations